Factores de riesgo en pacientes con enfermedad de Kawasaki con falla al tratamiento inicial con inmunoglobulina humana intravenosa en menores de 15 años atendidos en el Hospital del Niño del 1 de Enero de 2003 al 31 de Diciembre del 2013

Levy, Jacqueline; McLenan, Milene.
Pediátr. Panamá ; 44(1): 7-15, Abril-Mayo 2015.
Artículo en Español | LILACS | ID: biblio-848687

Documentos relacionados

  1. Immunoglobulin-resistant Kawasaki disease.
  2. Intravenous immunoglobulin G use and pharmacovigilance in a tertiary care children's hospital.
  3. Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells.
  4. Hemolytic anemia associated with intravenous immunoglobulin in Kawasaki disease.
  5. Psoriasiform dermatitis following intravenous immunoglobulin therapy: A case series.
  6. Clinical characteristics and course of patients with Kawasaki disease at a general hospital.
  7. [Chronic kidney disease in adults with primary immunodeficiency diseases in treatment with intravenous immunoglobulin].
  8. Intravenous immunoglobulin alteration in response to adverse reactions in neurological conditions: A retrospective cohort study.
  9. Ultra-high dose of intravenous immunoglobulin restores strength and motor function in a patient with refractory multifocal motor neuropathy.
  10. Intravenous Immunoglobulin Use In Critically Ill Children.